Antiretroviral Management Charts and Tables

Access Information

		FDA-Approved and Investigational Antiretrovirals HIV InSite. Comprehensive chart of FDA-approved and experimental drugs.

		Expanded Access, Compassionate Use, and Treatment IND Programs HIV InSite. Listing of programs that provide patients with limited access to promising experimental treatments before the medications have been given full approval by the U.S. Food and Drug Administration. November 2007.

		Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan (PEPFAR) U.S. Food and Drug Administration. Table detailing FDA approvals as part of a special initative for granting approval to manufacturers of generic antiretrovirals so that these drugs may be purchased for use outside the U.S. and paid for with PEPFAR funding.

Adverse Effects

		Adverse Effects of Antiretroviral Drugs Ian McNicholl, PharmD, BCPS, University of California San Francisco. July 2009.

		Adverse Events Due to Nonantiretroviral Medications during Treatment of HIV-Related Infections and Complications Ian McNicholl, PharmD, BCPS, and Christine Jamjian, PharmD, University of California San Francisco. July 2009.

		Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents Table 13: ART Associated Adverse Effects and Management Recommendations [PDF, 498K] Panel on Antiretroviral Guidelines for Adult and Adolescents. U.S. Department of Health and Human Services. November 3, 2008.

Drug Characteristics

		Antiretroviral Drug Profiles Susa Coffey, MD and Laurence Peiperl, MD. University of California, San Francisco.

		Currently Approved Drugs for HIV: A Comparative Chart AIDSmeds.com. Table showing standard antiretroviral dosages, plus dosing and side effect considerations and links to in-depth drug monographs.

Drug Interactions

		Database of Antiretroviral Drug Interactions HIV InSIte, Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Create custom reports with this interactive tool.

		Dosage Adjustments for ARV-ARV Drug Interactions Susa Coffey, MD and Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. July 2009.

		Drugs That Should Not Be Used With PIs, NNRTIs, or CCR5 Antagonists Table 14 from the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents [PDF, 318K]

		Etravirine-ARV Interactions Susa Coffey, MD, HIV InSite Medical Editor; Ian R. McNicholl, PharmD, HIV InSite Pharmacy Editor. July 2009. Reference table to help clinicians navigate the complexities of drug interactions with this NNRTI.

		Interactions between ARVs and Statin Medications: Recommendations for Coadministration of PIs and NNRTIs with Statins Susa Coffey, MD, HIV InSite Medical Editor. July 2009.

		Recreational Drugs and HIV Antivirals: A Guide to Interactions for Clinicians Christine Kubin, PharmD and Antonio Urbina, MD, New York/New Jersey AIDS Education Training Center. 2008. Contains information on interactions with alcohol, street drugs, and erectile dysfuntion agents.

Regimen Selection / Treatment Strategy

		Options for Once-Daily Dosing of Antiretroviral Drugs Susa Coffey, MD, University of California San Francisco. October 2007. Tables showing potential once-daily antiretroviral medications and regimens.

Summary tables from the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Panel on Antiretroviral Guidelines for Adult and Adolescents. U.S. Department of Health and Human Services. 2008.


	When to Start Treatment (Table 5a)


	Risks and Benefits of Starting Therapy at Higher CD4 Counts (Table 5b)


	ARV Therapy for Treatment Naive patients (Table 6)


	Advantages and Disadvantages of Components Recommended as Initial Therapy (Table 7)


	Components Not Recommended as Initial Therapy (Table 8)


	Components That Should Not be Offered at Any Time (Table 9)

Special Situations

		Dosing of Antiretroviral Drugs in Adults with Chronic Kidney Disease and Hemodialysis Ian R. McNicholl, PharmD, BCPS, and Rudolph A. Rodriguez, MD, University of California San Francisco. October 2009.

		Dosing for Ritonavir-Boosted Protease Inhibitors Susa Coffey, MD and Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. July 2009.